PsychoGenics

PsychoGenics is a specialized preclinical CRO with deep expertise in neuroscience, leveraging proprietary AI-enabled platforms (Cube technologies) to enhance drug discovery efficiency. The company serves pharmaceutical and biotech clients, offering end-to-end services from target validation to IND-enabling studies, with a focus on CNS and orphan disorders. It has established a strong track record with over 400 client relationships and recurrent business from more than 70% of its clients, supported by significant non-dilutive funding like NIH contracts and SBIR grants. While primarily a service provider, its AI platforms and disease models position it as a technology-enabled partner in the drug discovery value chain.

Proprietary AI-enabled in vivo screening platforms (SmartCube®, NeuroCube®, PhenoCube®, eCube™) that use machine learning to analyze complex behavioral and electrophysiological data for unbiased drug discovery and mechanism identification in CNS disorders.

PsychoGenics competes with large, global preclinical CROs (e.g., Charles River Laboratories, Labcorp) that offer broad services, and with other specialized neuroscience-focused CROs. Its key differentiator is its suite of proprietary, AI-driven phenotypic screening platforms (Cube technologies), which offer a unique, data-driven approach to de-risking early CNS drug discovery.